Scientists track fuel sources of leukemia cells in patients
NCT ID NCT04785989
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how cancer cells in chronic lymphocytic leukemia (CLL) use nutrients like sugar and glutamine. Researchers will give participants special labeled nutrients and then measure how the cells process them. The goal is to understand cancer cell metabolism better, not to treat the disease. About 16 adults with CLL or healthy volunteers will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 16 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2022
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
To meet the study aims sixteen (16) adult participants will be enrolled: four (4) healthy volunteers defined as people without a history of cancer, 8 patients with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0, and 4 patients with high disease burden CLL defined as having extensive infiltration of the bone marrow.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Group A * Adult (18 years of age or older) * No previous history of cancer * Routine history of normal blood counts and vital signs * Documented Informed Consent Group B * Adult (18 years of age or older) * Diagnosis of CLL with low disease burden defined as Rai stage 0 ((Lymphocytosis; no enlargement of the lymph nodes, spleen, or liver; red blood cell and platelet counts are near normal.) * Treatment naïve * Documented Informed Consent Group C * Adult (18 years of age or older) * Diagnosis of CLL with high systemic disease burden defined as infiltration of bone marrow causing cytopenia * Treatment naïve * Able/willing to have bone marrow aspiration * Documented Informed Consent Exclusion Criteria: For all participants * Prisoners * Psychiatric inpatients or people who are institutionalized * Minor (Less than 18 years of age) * History of diabetes * Cannot be on antihyperglycemic therapy * Carbohydrate restricting diets: Atkins, Vegan, Ketogenic, etc. * Females of child bearing potential * Persons without decision-making capacity * Person who cannot read/write English * Not meeting inclusion criteria defined above
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo aims to push CLL into deep remission
- Can a new BTK inhibitor outsmart resistance in CLL?
- Can a new pill outsmart Drug-Resistant leukemia?
- Can engineered immune cells beat tough B-Cell cancers?
- Can a targeted drug outperform chemo for a common blood cancer?
- Can a triple drug combo outsmart High-Risk CLL?